Met (L6E7) Mouse mAb

Met (L6E7) Mouse mAb Suppliers list
Company Name: Cell Signaling Technology Inc  
Tel: 21-80243558 86218024
Email: info@cellsignal.cn
Company Name: Beijing Dongling Technology Co., Ltd.  
Tel: 13051591126
Email:
Company Name: Shanghai Tuoran Biotechnology Co., Ltd.  
Tel: 18621916228
Email:
Company Name: Gene Biotechnology International Trading (Shanghai) Co., Ltd. Guangzhou Branch  
Tel: 15107906345
Email:
Company Name: Shanghai Beinuo Biotechnology Co., Ltd.  
Tel: 021-57730393 15800960770
Email: beinuobio@163.com
Met (L6E7) Mouse mAb Basic information
Source Reactivity Background References
Product Name:Met (L6E7) Mouse mAb
Synonyms:Met (L6E7) Mouse mAb
CAS:
MF:
MW:0
EINECS:
Product Categories:
Mol File:Mol File
Met (L6E7) Mouse mAb Structure
Met (L6E7) Mouse mAb Chemical Properties
Safety Information
MSDS Information
Met (L6E7) Mouse mAb Usage And Synthesis
SourceMouse
ReactivityHuman
BackgroundMet, a high affinity tyrosine kinase receptor for hepatocyte growth factor is a disulfide-linked heterodimer made of 45 kDa α- and 145 kDa β-subunits. The α-subunit and the amino-terminal region of the β-subunit form the extracellular domain. The remainder of the β-chain spans the plasma membrane and contains a cytoplasmic region with tyrosine kinase activity. Interaction of Met with HGF results in autophosphorylation at multiple tyrosines, which recruit several downstream signaling components, including Gab1, c-Cbl, and PI3 kinase. These fundamental events are important for all of the biological functions involving Met kinase activity. The addition of a phosphate at cytoplasmic Tyr1003 is essential for Met protein ubiquitination and degradation. Phosphorylation at Tyr1234/1235 in the Met kinase domain is critical for kinase activation. Phosphorylation at Tyr1349 in the Met cytoplasmic domain provides a direct binding site for Gab1. Research studies have shown that altered Met levels and/or tyrosine kinase activities are found in several types of tumors, including renal, colon, and breast. Thus, investigators have concluded that Met is an attractive potential cancer therapeutic and diagnostic target.
References[1] Cooper, C.S. et al. (1984) Nature 311, 29-33.
[2] Bottaro, D.P. et al. (1991) Science 251, 802-4.
[3] Bardelli, A. et al. (1997) Oncogene 15, 3103-11.
[4] Taher, T.E. et al. (2002) J Immunol 169, 3793-800.
[5] Schaeper, U. et al. (2000) J Cell Biol 149, 1419-32.
[6] Eder, J.P. et al. (2009) Clin Cancer Res 15, 2207-14.
[7] Sattler, M. and Salgia, R. (2009) Update Cancer Ther 3, 109-118.
Met (L6E7) Mouse mAb Preparation Products And Raw materials
Tag:Met (L6E7) Mouse mAb Related Product Information